BR0314139A - Derivados de 1,4-pirazina substituìdos - Google Patents

Derivados de 1,4-pirazina substituìdos

Info

Publication number
BR0314139A
BR0314139A BR0314139-0A BR0314139A BR0314139A BR 0314139 A BR0314139 A BR 0314139A BR 0314139 A BR0314139 A BR 0314139A BR 0314139 A BR0314139 A BR 0314139A
Authority
BR
Brazil
Prior art keywords
substituted
pyrazine derivatives
derivatives
pyrazine
anxiety
Prior art date
Application number
BR0314139-0A
Other languages
English (en)
Inventor
Jeffrey W Corbett
Jian-Min Fu
Michael D Ennis
Kristine E Frank
Robert L Hoffman
Patrick R Verhoest
Original Assignee
Pharmacia & Upjohn Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Co Llc filed Critical Pharmacia & Upjohn Co Llc
Publication of BR0314139A publication Critical patent/BR0314139A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms

Abstract

"DERIVADOS DE 1,4-PIRAZINA SUBSTITUìDOS". São descritos derivados 1,4-pirazina substituídos de arila e a sua utilização no tratamento de distúrbios de ansiedade, depressão e distúrbios relacionados ao estresse.
BR0314139-0A 2002-09-12 2003-08-27 Derivados de 1,4-pirazina substituìdos BR0314139A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41026102P 2002-09-12 2002-09-12
PCT/US2003/024805 WO2004024719A1 (en) 2002-09-12 2003-08-27 Substituted 1,4-pyrazine derivatives

Publications (1)

Publication Number Publication Date
BR0314139A true BR0314139A (pt) 2005-07-12

Family

ID=31994096

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0314139-0A BR0314139A (pt) 2002-09-12 2003-08-27 Derivados de 1,4-pirazina substituìdos

Country Status (10)

Country Link
US (1) US20040116444A1 (pt)
EP (1) EP1539736A1 (pt)
JP (1) JP2006506350A (pt)
AR (1) AR041125A1 (pt)
AU (1) AU2003269949A1 (pt)
BR (1) BR0314139A (pt)
CA (1) CA2494975A1 (pt)
MX (1) MXPA05002418A (pt)
TW (1) TW200503717A (pt)
WO (1) WO2004024719A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006525993A (ja) * 2003-05-09 2006-11-16 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー Ｃｒｆ１受容体拮抗剤である化合物
US20060211710A1 (en) * 2005-03-17 2006-09-21 Pfizer Inc Substituted aryl 1,4-pyrazine derivatives
CN116478132A (zh) * 2016-07-12 2023-07-25 锐新医药公司 作为变构shp2抑制剂的2,5-双取代型及2,5,6-三取代型3-甲基吡嗪
MX2019008696A (es) 2017-01-23 2019-09-13 Revolution Medicines Inc Compuestos de piridina como inhibidores de shp2 alostericos.
MX2019008695A (es) 2017-01-23 2019-09-11 Revolution Medicines Inc Compuestos biciclicos como inhibidores alostericos de shp2.
CA3074690A1 (en) 2017-09-07 2019-03-14 Revolution Medicines, Inc. Shp2 inhibitor compositions and methods for treating cancer
EP3694848A1 (en) 2017-10-12 2020-08-19 Revolution Medicines, Inc. Pyridine, pyrazine, and triazine compounds as allosteric shp2 inhibitors
EP3724189B1 (en) 2017-12-15 2023-10-04 Revolution Medicines, Inc. Polycyclic compounds as allosteric shp2 inhibitors
PE20212112A1 (es) 2018-05-01 2021-11-04 Revolution Medicines Inc Analogos de rapamicina ligados a c40, c28 y c-32 como inhibidores de mtor
CA3098698A1 (en) 2018-05-01 2019-11-07 Revolution Medicines, Inc. C26-linked rapamycin analogs as mtor inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE213495T1 (de) * 1996-09-16 2002-03-15 Du Pont Pharm Co Eine resorbierbare röntgenopake markierung enthaltendes chirurgisches implantat und verfahren zum verriegeln desselben in einem körper
PA8467401A1 (es) * 1998-02-17 2000-09-29 Pfizer Prod Inc Procedimiento para tratar la insuficiencia cardiaca
IL139197A0 (en) * 1999-10-29 2001-11-25 Pfizer Prod Inc Use of corticotropin releasing factor antagonists and related compositions
WO2001060806A2 (en) * 2000-02-16 2001-08-23 Neurogen Corporation Substituted arylpyrazines

Also Published As

Publication number Publication date
US20040116444A1 (en) 2004-06-17
AR041125A1 (es) 2005-05-04
TW200503717A (en) 2005-02-01
MXPA05002418A (es) 2005-05-27
JP2006506350A (ja) 2006-02-23
EP1539736A1 (en) 2005-06-15
WO2004024719A1 (en) 2004-03-25
CA2494975A1 (en) 2004-03-25
AU2003269949A1 (en) 2004-04-30

Similar Documents

Publication Publication Date Title
DK1446387T3 (da) Substituerede aryl, 1,4-pyrazinderivater
ES2135062T3 (es) Pirazolo y pirrolopiridinas.
DE60010098D1 (de) 28-epirapaloge
DK0833839T3 (da) Heterocykliske peptidylforbindelser, der er nyttige til behandling af thrombinrelaterede sygdomme
DK1224297T3 (da) Alzheimers sygdom -sekretase, APP-substrater derfor og anvendelser deraf
ITRM20020264A0 (it) Articolo assorbente e procedimento per la sua fabbricazione.
BR0215405A (pt) Composições e processos de uso de collajolie
BRPI0413449A (pt) compostos de quinoxalina
SE9802729D0 (sv) Novel Compounds
DE60334379D1 (de) Copolymerverbindung, diese enthaltende polymerzusammensetzung, bilderzeugungsverfahren und dieselbe benutzende bilderzeugungsvorrichtung
HRP20050439B1 (en) New use of dextran sulfate
NO20044898L (no) Nye etonogestrel estere
ATE265454T1 (de) Phenyloxazol-1,4-diazabicyclo(3.2.2)nonanderiva e,ihre herstellung und ihre therapeutische verwendung
DE50310977D1 (de) Kompaktiertes menthol
BR0314139A (pt) Derivados de 1,4-pirazina substituìdos
TR200402030T4 (tr) İkame edilen I-aminobutan-3-ol-türevleri
BR0016941A (pt) Derivados de aminometil-fenil-ciclohexanona
BR0316544A (pt) Compostos calcilìticos
DK1461042T3 (da) Anvendelse af desoxypeganin til behandling af klinisk depression
NO20005548L (no) Mykobakterieinhibitorer
ATE277924T1 (de) Aryl-8-azabicyclo(3.2.1)octanes für die behandlung von depression
DE60018253D1 (de) Die Verwendung von 5-Carboxanilido-2,4-bis-trifluoromethylthiazole gegen Reisbräune
BRPI0411382A (pt) derivados de 2-aminobenzoil
DE60131170D1 (de) Künstliche Lunge des Membrantyps
TR200003084T2 (tr) Paroxetine askorbat

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.